Your session is about to expire
← Back to Search
Chemotherapy + Midostaurin for Acute Myeloid Leukemia
Study Summary
This trial is testing whether adding midostaurin to standard chemotherapy improves treatment outcomes in patients with FLT3-positive acute myeloid leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I developed AML as a result of treatment for another cancer.I haven't had chemotherapy for leukemia or myelodysplasia, except in emergencies.I am a woman who can have children and am not using two forms of birth control.I am a man and will use a latex condom during sex while on treatment and for 12 weeks after.I have been diagnosed with AML, not including type M3.I am between 18 and 59 years old.My leukemia has a FLT3 mutation.I have symptoms of heart failure.
- Group 1: Induction and consolidation chemotherapy plus midostaurin
- Group 2: Induction and consolidation chemotherapy plus placebo
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the potential side effects of cytarabine for patients?
"Cytarabine has received a safety score of 3 from our team at Power. This is because, as a Phase 3 trial, there is both some evidence of its efficacy as well as multiple rounds of data supporting its safety."
Might this research be appropriate for patients who are no longer considered young adults?
"The age requirements for participants in this trial are between 18 and 59 years old."
Are there any prerequisites that participants must meet before enrolling in this research project?
"The ideal candidate for this leukemia trial is between 18-59 years old. Out of the 717 people that the researchers are looking for, how many might you be able to help them find?"
Do we have a history of using cytarabine in previous medical trials?
"As of now, 285 studies concerning cytarabine are active with 69 of those in the third stage of testing. Although a large concentration of these studies take place in Providence, Rhode island, there are 12,819 locations running cytarabine trials in total."
Share this study with friends
Copy Link
Messenger